Startseite>>UPGL00004

UPGL00004

Katalog-Nr.GC61365

UPGL00004 ist ein potenter allosterischer Glutaminase C (GAC)-Inhibitor (IC50=29 nM; Kd=27 nM). UPGL00004 hemmt stark die Proliferation hochaggressiver dreifach negativer Brustkrebszelllinien.

Products are for research use only. Not for human use. We do not sell to patients.

UPGL00004 Chemische Struktur

Cas No.: 1890169-95-5

Größe Preis Lagerbestand Menge
10mM (in 1mL DMSO)
95,00 $
Auf Lager
5mg
81,00 $
Auf Lager
10mg
144,00 $
Auf Lager
50mg
495,00 $
Auf Lager
100mg
855,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

UPGL00004 is a potent allosteric glutaminase C (GAC) inhibitor (IC50=29 nM; Kd=27 nM). UPGL00004 strongly inhibits the proliferation of highly aggressive triple-negative breast cancer cell lines[1].

UPGL00004 inhibits MDA-MB-231, HS578T and TSE cells with IC50s of 70, 129, and 262 nM, respectively[1].

The combination of UPGL00004 (1 mg/kg body weight) and Bevacizumab (2.5 mg/kg body weight) via intraperitoneal injection completely prevent any detectable increase in tumor size in a triple-negative breast cancer patient-derived tumor graft model[1].

[1]. Huang Q, et al. Characterization of the interactions of potent allosteric inhibitors with glutaminase C, a key enzyme in cancer cell glutamine metabolism. J Biol Chem. 2018 Mar 9;293(10):3535-3545.

Bewertungen

Review for UPGL00004

Average Rating: 5 ★★★★★ (Based on Reviews and 9 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for UPGL00004

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.